241 related articles for article (PubMed ID: 29080043)
1. PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line.
Di Pasquale C; Gentilin E; Falletta S; Bellio M; Buratto M; Degli Uberti E; Chiara Zatelli M
Endocrine; 2018 May; 60(2):308-316. PubMed ID: 29080043
[TBL] [Abstract][Full Text] [Related]
2. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.
Rui QH; Ma JB; Liao YF; Dai JH; Cai ZY
Braz J Med Biol Res; 2019; 52(4):e7728. PubMed ID: 30994730
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
4. AFAP1-AS1 Promotes Proliferation of Pituitary Adenoma Cells through miR-103a-3p to Activate PI3K/AKT Signaling Pathway.
Tang H; Zhu D; Zhang G; Luo X; Xie W
World Neurosurg; 2019 Oct; 130():e888-e898. PubMed ID: 31299308
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.
Xie R; He WQ; Shen M; Shou XF; Wang YF; Bao WM; Zhao Y
J Neurooncol; 2015 Oct; 125(1):79-89. PubMed ID: 26297046
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
Lau MT; Leung PC
Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas.
Monsalves E; Juraschka K; Tateno T; Agnihotri S; Asa SL; Ezzat S; Zadeh G
Endocr Relat Cancer; 2014 Aug; 21(4):R331-44. PubMed ID: 25052915
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone-stimulated insulin-like growth factor-1 expression in rainbow trout (Oncorhynchus mykiss) hepatocytes is mediated by ERK, PI3K-AKT, and JAK-STAT.
Reindl KM; Kittilson JD; Bergan HE; Sheridan MA
Am J Physiol Regul Integr Comp Physiol; 2011 Jul; 301(1):R236-43. PubMed ID: 21490369
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for luteinizing hormone induction of growth hormone gene transcription in fish model: crosstalk of the cAMP/PKA pathway with MAPK-and PI3K-dependent cascades.
Sun C; He M; Ko WK; Wong AO
Mol Cell Endocrinol; 2014 Feb; 382(2):835-50. PubMed ID: 24161589
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
13. Aberrant IGF1-PI3K/AKT/MTOR signaling pathway regulates the local immunity of oral lichen planus.
Ma RJ; Tan YQ; Zhou G
Immunobiology; 2019 May; 224(3):455-461. PubMed ID: 30773287
[TBL] [Abstract][Full Text] [Related]
14. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
[TBL] [Abstract][Full Text] [Related]
15. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
16. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
[TBL] [Abstract][Full Text] [Related]
17. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
18. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
19. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
20. AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback.
Qin L; Wang Y; Tao L; Wang Z
J Biochem; 2011 Aug; 150(2):151-6. PubMed ID: 21616916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]